Ustekinumab for the treatment of psoriatic arthritis

An update

Parastoo Davari, Michael S. Leo, Faranak Kamangar, Nasim Fazel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalClinical, Cosmetic and Investigational Dermatology
Volume7
DOIs
StatePublished - Sep 2 2014

Fingerprint

Psoriatic Arthritis
United States Food and Drug Administration
Psoriasis
Therapeutics
Randomized Controlled Trials
Monoclonal Antibodies
Safety
Ustekinumab

Keywords

  • Psoriasis
  • Psoriatic arthritis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Ustekinumab for the treatment of psoriatic arthritis : An update. / Davari, Parastoo; Leo, Michael S.; Kamangar, Faranak; Fazel, Nasim.

In: Clinical, Cosmetic and Investigational Dermatology, Vol. 7, 02.09.2014, p. 243-249.

Research output: Contribution to journalArticle

Davari, Parastoo ; Leo, Michael S. ; Kamangar, Faranak ; Fazel, Nasim. / Ustekinumab for the treatment of psoriatic arthritis : An update. In: Clinical, Cosmetic and Investigational Dermatology. 2014 ; Vol. 7. pp. 243-249.
@article{fa2e768b0e244eddb7c160787475eb79,
title = "Ustekinumab for the treatment of psoriatic arthritis: An update",
abstract = "Psoriatic arthritis occurs in 30{\%} of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.",
keywords = "Psoriasis, Psoriatic arthritis, Ustekinumab",
author = "Parastoo Davari and Leo, {Michael S.} and Faranak Kamangar and Nasim Fazel",
year = "2014",
month = "9",
day = "2",
doi = "10.2147/CCID.S50003",
language = "English (US)",
volume = "7",
pages = "243--249",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ustekinumab for the treatment of psoriatic arthritis

T2 - An update

AU - Davari, Parastoo

AU - Leo, Michael S.

AU - Kamangar, Faranak

AU - Fazel, Nasim

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

AB - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

KW - Psoriasis

KW - Psoriatic arthritis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84907879772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907879772&partnerID=8YFLogxK

U2 - 10.2147/CCID.S50003

DO - 10.2147/CCID.S50003

M3 - Article

VL - 7

SP - 243

EP - 249

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -